Results of Phase I Monotherapy Trial

• In Phase I studies, brigimadlin had a manageable safety profile^1,2

• DLTs were mainly thrombocytopenia and neutropenia²

  – The MTD of brigimadlin was 60 mg Q3W

  – The RDE was selected as 45 mg Q3W

• Nausea was the most common TRAE; antiemetic prophylaxis or treatment was implemented²

• Neutropenia and thrombocytopenia were the most common grade ≥3 TRAEs¹

Zoom

1. LoRusso P, et al. ASCO 2023. Poster 11554; 2. Gounder M, et al. CTOS 2022. Oral Presentation #19.

• In patients with MDM2-amplified DDLPS (69 patients), preliminary median PFS was 7.9 months (95% CI: 4.2–9.9) and ORR was 14.5%¹

  – 10/69 (14.5%) patients achieved a PR

  – A further 47 (68.1%) patients had SD

  – DCR was 82.6%¹

Zoom

As of August 2022, 27 patients have received brigimadlin plus ezabenlimab at 30 mg (n=13) and at 45 mg (n=14)

Phase I safety data

• Brigimadlin plus ezabenlimab showed a manageable safety profile, including in patients with liposarcoma

• Most common any-cause grade ≥3 AEs were anemia (n=7), thrombocytopenia (n=7), and lymphocyte count decreased (n=6)

• The RDE was selected as brigimadlin at 45 mg Q3W + ezabenlimab 240 mg

Zoom

Early antitumor activity

• Among response-evaluable patients who received brigimadlin plus ezabenlimab:

  – 8 of 24 patients (33%) achieved PR

  – 14 of 24 patients (58%) had SD

Zoom